Nonsteroidal anti-inflammatory drugs and lung cancer risk: A population-based case control study

Richard J. Wall, Yu Shyr, Walter Smalley

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND: It remains unknown whether nonsteroidal anti-inflammatory drugs (NSAIDs) confer a protective effect against lung cancer development. We examined the relationship between NSAID exposure and subsequent lung cancer development in a large statewide, population-based cohort. DESIGN: Nested case-control study in the Tennessee Medicaid population from 1990 to 2000. METHODS: Lung cancer cases were identified using a statewide computerized claims database. Each time a case was identified, age- and sex-matched controls were randomly selected from the available source population. A detailed pharmacy database quantified nonsteroidal anti-inflammatory drug (NSAID) exposure during the 5 years before cancer diagnosis, and conditional logistic regression was used to examine the relationship between NSAID exposure and lung cancer development. Identical analyses were repeated in a subpopulation of high-risk individuals with chronic obstructive pulmonary disease (COPD). RESULTS: 303,399 persons were enrolled in the study population. During 1.9 million person-years of follow-up (median 6.3 years per person), 3,370 lung cancer cases were identified. Among those ever using NSAIDs, the adjusted odds ratio of developing lung cancer was 1.03 (95% confidence interval: 0.94-1.12). Among those using >24 months of NSAIDs in the 5 years before lung cancer diagnosis, the adjusted odds ratio for lung cancer was 0.96 (95% confidence interval: 0.82-1.11), and no protective effect was demonstrated in any NSAID exposure stratum. Similarly, among the 2519 high-risk individuals with chronic obstructive pulmonary disease, no significant protective effect from NSAIDs was noted. CONCLUSION: This large statewide, population-based study did not demonstrate a protective effect of NSAIDs on lung cancer development in either the general or high-risk chronic obstructive pulmonary disease populations.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalJournal of Thoracic Oncology
Volume2
Issue number2
DOIs
Publication statusPublished - 2007 Jan 1

Fingerprint

Case-Control Studies
Lung Neoplasms
Anti-Inflammatory Agents
Pharmaceutical Preparations
Population
Chronic Obstructive Pulmonary Disease
Odds Ratio
Databases
Confidence Intervals
Medicaid
Logistic Models
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

@article{969ea291ca264c82befecfcdf525f249,
title = "Nonsteroidal anti-inflammatory drugs and lung cancer risk: A population-based case control study",
abstract = "BACKGROUND: It remains unknown whether nonsteroidal anti-inflammatory drugs (NSAIDs) confer a protective effect against lung cancer development. We examined the relationship between NSAID exposure and subsequent lung cancer development in a large statewide, population-based cohort. DESIGN: Nested case-control study in the Tennessee Medicaid population from 1990 to 2000. METHODS: Lung cancer cases were identified using a statewide computerized claims database. Each time a case was identified, age- and sex-matched controls were randomly selected from the available source population. A detailed pharmacy database quantified nonsteroidal anti-inflammatory drug (NSAID) exposure during the 5 years before cancer diagnosis, and conditional logistic regression was used to examine the relationship between NSAID exposure and lung cancer development. Identical analyses were repeated in a subpopulation of high-risk individuals with chronic obstructive pulmonary disease (COPD). RESULTS: 303,399 persons were enrolled in the study population. During 1.9 million person-years of follow-up (median 6.3 years per person), 3,370 lung cancer cases were identified. Among those ever using NSAIDs, the adjusted odds ratio of developing lung cancer was 1.03 (95{\%} confidence interval: 0.94-1.12). Among those using >24 months of NSAIDs in the 5 years before lung cancer diagnosis, the adjusted odds ratio for lung cancer was 0.96 (95{\%} confidence interval: 0.82-1.11), and no protective effect was demonstrated in any NSAID exposure stratum. Similarly, among the 2519 high-risk individuals with chronic obstructive pulmonary disease, no significant protective effect from NSAIDs was noted. CONCLUSION: This large statewide, population-based study did not demonstrate a protective effect of NSAIDs on lung cancer development in either the general or high-risk chronic obstructive pulmonary disease populations.",
author = "Wall, {Richard J.} and Yu Shyr and Walter Smalley",
year = "2007",
month = "1",
day = "1",
doi = "10.1097/jto.0b013e31802f1cc5",
language = "English",
volume = "2",
pages = "109--114",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "2",

}

Nonsteroidal anti-inflammatory drugs and lung cancer risk : A population-based case control study. / Wall, Richard J.; Shyr, Yu; Smalley, Walter.

In: Journal of Thoracic Oncology, Vol. 2, No. 2, 01.01.2007, p. 109-114.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nonsteroidal anti-inflammatory drugs and lung cancer risk

T2 - A population-based case control study

AU - Wall, Richard J.

AU - Shyr, Yu

AU - Smalley, Walter

PY - 2007/1/1

Y1 - 2007/1/1

N2 - BACKGROUND: It remains unknown whether nonsteroidal anti-inflammatory drugs (NSAIDs) confer a protective effect against lung cancer development. We examined the relationship between NSAID exposure and subsequent lung cancer development in a large statewide, population-based cohort. DESIGN: Nested case-control study in the Tennessee Medicaid population from 1990 to 2000. METHODS: Lung cancer cases were identified using a statewide computerized claims database. Each time a case was identified, age- and sex-matched controls were randomly selected from the available source population. A detailed pharmacy database quantified nonsteroidal anti-inflammatory drug (NSAID) exposure during the 5 years before cancer diagnosis, and conditional logistic regression was used to examine the relationship between NSAID exposure and lung cancer development. Identical analyses were repeated in a subpopulation of high-risk individuals with chronic obstructive pulmonary disease (COPD). RESULTS: 303,399 persons were enrolled in the study population. During 1.9 million person-years of follow-up (median 6.3 years per person), 3,370 lung cancer cases were identified. Among those ever using NSAIDs, the adjusted odds ratio of developing lung cancer was 1.03 (95% confidence interval: 0.94-1.12). Among those using >24 months of NSAIDs in the 5 years before lung cancer diagnosis, the adjusted odds ratio for lung cancer was 0.96 (95% confidence interval: 0.82-1.11), and no protective effect was demonstrated in any NSAID exposure stratum. Similarly, among the 2519 high-risk individuals with chronic obstructive pulmonary disease, no significant protective effect from NSAIDs was noted. CONCLUSION: This large statewide, population-based study did not demonstrate a protective effect of NSAIDs on lung cancer development in either the general or high-risk chronic obstructive pulmonary disease populations.

AB - BACKGROUND: It remains unknown whether nonsteroidal anti-inflammatory drugs (NSAIDs) confer a protective effect against lung cancer development. We examined the relationship between NSAID exposure and subsequent lung cancer development in a large statewide, population-based cohort. DESIGN: Nested case-control study in the Tennessee Medicaid population from 1990 to 2000. METHODS: Lung cancer cases were identified using a statewide computerized claims database. Each time a case was identified, age- and sex-matched controls were randomly selected from the available source population. A detailed pharmacy database quantified nonsteroidal anti-inflammatory drug (NSAID) exposure during the 5 years before cancer diagnosis, and conditional logistic regression was used to examine the relationship between NSAID exposure and lung cancer development. Identical analyses were repeated in a subpopulation of high-risk individuals with chronic obstructive pulmonary disease (COPD). RESULTS: 303,399 persons were enrolled in the study population. During 1.9 million person-years of follow-up (median 6.3 years per person), 3,370 lung cancer cases were identified. Among those ever using NSAIDs, the adjusted odds ratio of developing lung cancer was 1.03 (95% confidence interval: 0.94-1.12). Among those using >24 months of NSAIDs in the 5 years before lung cancer diagnosis, the adjusted odds ratio for lung cancer was 0.96 (95% confidence interval: 0.82-1.11), and no protective effect was demonstrated in any NSAID exposure stratum. Similarly, among the 2519 high-risk individuals with chronic obstructive pulmonary disease, no significant protective effect from NSAIDs was noted. CONCLUSION: This large statewide, population-based study did not demonstrate a protective effect of NSAIDs on lung cancer development in either the general or high-risk chronic obstructive pulmonary disease populations.

UR - http://www.scopus.com/inward/record.url?scp=34247149844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247149844&partnerID=8YFLogxK

U2 - 10.1097/jto.0b013e31802f1cc5

DO - 10.1097/jto.0b013e31802f1cc5

M3 - Article

C2 - 17410024

AN - SCOPUS:34247149844

VL - 2

SP - 109

EP - 114

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 2

ER -